Seeking Alpha

Peak Performance

 
View as an RSS Feed
View Peak Performance's Articles BY TICKER:
  • Dynavax Offers Both Potential Long-Term And Short-Term Trade Potential
    Mon, Aug. 4 AZN, CDC, GSK 3 Comments

    Summary

    • Both short and long-term trade possibilities.
    • Expecting Approval of Hepislav which is currently in Phase 3.
    • Recent Institutional Buying and Extremely High Relative Ownership.
  • Positive Trends For ImmunoCellular Therapeutics
    Mon, Jun. 9 IMUC 40 Comments

    Summary

    • Encouraging data presented at American Society of Clinical Oncology.
    • Phase III Study of ICT-107 for Glioblastoma Expected.
    • Relatively High Analyst Price Targets.
  • Expecting Continued Increase In Capstone's Share Price
    Mon, Jun. 2 FCEL, PLUG, CPST 32 Comments

    Summary

    • Obama factor expected to provide immediate upside.
    • Attractiveness of capstone relative to fuel cells.
    • Expectations about upcoming earnings call.
  • ImmunoCellular Therapeutics: Potential Near-Term Upward Spike
    Tue, May. 20 IMUC 27 Comments

    Summary

    • Imminent Presentation at Prestigious Annual Meeting of the American Society of Clinical Oncology (ASCO) Could Re-ignite the Stock.
    • Existing, Evolving Data Demonstrating ICT-107’s Superiority to the Existing Standard of Care.
    • Extremely oversold situation offers an exceptional risk-reward ratio - especially in the very near-term.
  • Capstone: Extreme Sell-Off And Reliance Upon Misinformation Creates Tremendous Entry Point
    Mon, May. 12 CPST 36 Comments

    Summary

    • Extreme sell-off of nearly 40% in 10 trading days creates a tremendous entry opportunity.
    • Over-reactive sell-off was partly based on reliance upon misinformation.
    • Reasonably expected near-term operational performance and developments warrant a much higher stock price.
  • Capstone Part 3: Still Triple Value Bound
    Tue, May. 6 FCEL, CPST 12 Comments

    Summary

    • Current buying opportunity created by announcement of equity offering.
    • Data on previous equity offerings that created double-digit returns within weeks.
    • Continued favorable developments.
  • Galectin Therapeutics - Great Buying Opportunity
    Mar. 27, 2013 GALT 11 Comments
  • Capstone Part 2: Bounding Towards Triple Value
    Sep. 14, 2012 AONEQ, FCEL, JASO 14 Comments
  • Expecting Further Upside Movement On Zalicus
    Aug. 14, 2012 COV, NVS, SNY 20 Comments
  • Capstone Turbine Technicals Are Starting To Match Improving Fundamentals: Part 1
    Jul. 13, 2012 AONEQ, CAT, FCEL 8 Comments
  • Zalicus Is Trading At Bargain Levels
    Jul. 9, 2012 AMGN, COV, NVS 35 Comments